Objective: To screen the main active components of Erzhiwan against liver fibrosis

and predict the targets and signal pathways for anti-hepatic fibrosis. Method: Based on the ADME computing method

Traditional Chinese Medicine System Pharmacology platform (TCMSP) and other databases

as well as reverse molecular docking server (DRAR-CPI)

the active ingredients and the potential targets of of Erzhiwan for anti-hepatic fibrosis effects were predicted. Then by mapping with the anti-hepatic fibrosis targets in Human Genome annotation database (GeneCards)

the anti-hepatic fibrosis targets of Erzhiwan were screened. Cytoscape 3.5.1 software was used to construct the active ingredient-target network of Erzhiwan was constructed; the biological information annotation database (DAVID) was used for enrichment analysis of gene ontology (GO) biological process and Kyoto Encyclopedia of genes andgenomes (KEGG) metabolic pathway. Result: The 18 active components were screened from Erzhiwan

which acted on 114 targets

mainly involving 8 signaling pathways and 13 biological processes. Conclusion: The bioactive components of Erzhiwan can play an anti-hepatic fibrosis role through transforming growth factor-β (TGF-β)

mitogen activated protein kinase (MAPK)

phosphatidyl inositol 3-kinase(PI3K)/serine/threonine protein kinase (Akt) signal pathway (PI3K/Akt)

nuclear transcription factor-κB (NF-κB)

peroxisome proliferators-activated receptor (PPAR) and other signal pathways

protein phosphorylation

signal transduction and other biological processes

embodying the characteristics of multiple components

multiple targets and pathways of traditional Chinese medicine. This study provides a theoretical basis for further research on the efficacy of Erzhiwan against liver fibrosis and the explanation on its mechanism of anti-hepatic fibrosis.